SEARCH

SEARCH BY CITATION

References

  • 1
    Escudier B,Eisen T,Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125134.
  • 2
    Motzer RJ,Hutson TE,Tomczack P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115124.
  • 3
    Wilhelm S,Carter C,Tang L, et al. BAY-43–9006 exhibits broad oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 70997109.
  • 4
    Mendel DB,Laird AD,Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327337.
  • 5
    Szczylik C,Demkow T,Staehler M, et al. Randomized phase 2 trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma [abstract]. J Clin Oncol. 2007; 25( suppl): 241s. Abstract 5025.
  • 6
    Motzer RJ,Rini, BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295: 25162524.
  • 7
    Tamaskar I,Garcia JA,Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2007; 179: 8186.
  • 8
    Motzer RJ,Mazumdar M,Bacik J,Berg W,Amsterdam A,Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 25302540.
  • 9
    Rini BI,George DJ,Michaelson MD, et al. Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) [abstract]. Ann Oncol. 2006; 17: 144s. Abstract 438O.
  • 10
    Sablin MP,Bouaita L,Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract]. J Clin Oncol. 2007; 25( suppl): 244s. Abstract 5038.
  • 11
    Mizukami Y,Kohgo Y,Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007; 13: 56705674.
  • 12
    Thomas GV,Tran C,Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006; 12: 122127
  • 13
    Motzer RJ,Escudier B,Oudard S, et al. Efficiency of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008; 372: 449456.